LP
HZNP

LMR Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

LMR Partners’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,203,870
Closed -$139M – 1232
2023
Q3 		$139M Buy
1,203,870
+64,731
+6% +$6.96M 1.57% 9
2023
Q2 		$117M Buy
1,139,139
+332,933
+41% +$35.1M 1.3% 7
2023
Q1 		$88M Buy
806,206
+683,491
+557% +$75.5M 1.36% 6
2022
Q4 		$14M Buy
122,715
+115,215
+1,536% +$9.57M 0.24% 108
2022
Q3 		$464K Hold
7,500
– – 0.01% 901
2022
Q2 		$598K Buy
+7,500
New +$710K 0.01% 871
2020
Q4 		– Sell
-117,673
Closed -$9.14M – 725
2020
Q3 		$9.14M Buy
+117,673
New +$8.1M 0.19% 58
2019
Q4 		– Sell
-53,413
Closed -$1.45M – 639
2019
Q3 		$1.45M Hold
53,413
– – 0.07% 129
2019
Q2 		$1.28M Buy
+53,413
New +$1.35M 0.05% 190
2015
Q3 		– Sell
-48,343
Closed -$1.68M – 553
2015
Q2 		$1.68M Buy
+48,343
New +$1.48M 0.21% 138

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

LMR Partners's HZNP Position: Q4 2023 in Review

LMR Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 1,203,870 shares — an estimated $139M sold.

LMR Partners first reported a position in HZNP in Q2 2015 and held it in 10 quarters. The position peaked at $139M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • LMR Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • LMR Partners sold 1,203,870 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $139M.
  • LMR Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2015 and held it in 10 quarters.
  • LMR Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $139M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on LMR Partners's 13F filing for Q4 2023, filed 14 Feb 2024.